United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 5 minute read Pharma Industry News Viking Therapeutics’ GLP-1/GIP dual agonist VK2735 impresses at ObesityWeek 2025 with sustained weight-loss efficacy Find out how Viking Therapeutics’ VK2735 is redefining obesity treatment with sustained clinical results — see what this breakthrough means for patients and investors today! bySoujanya RaviNovember 6, 2025